comparemela.com
Home
Live Updates
NOXXON Pharma N.V.: NOXXON Presents Full Top-line Results From NOX-A12 Phase 1/2 GLORIA Trial in Glioblastoma at the 2022 ASCO Annual Meeting : comparemela.com
NOXXON Pharma N.V.: NOXXON Presents Full Top-line Results From NOX-A12 Phase 1/2 GLORIA Trial in Glioblastoma at the 2022 ASCO Annual Meeting
90% of patients achieve tumor size reductions 40% of patients achieve partial response, i.e. tumor size reductions of more than 50% Regulatory News: NOXXON Pharma N.V. (Euronext Growth
Related Keywords
Germany
,
Illinois
,
United States
,
Paris
,
France General
,
France
,
Bonn
,
Nordrhein Westfalen
,
Chicago
,
American
,
German
,
Arthur Rouill
,
Aram Mangasarian
,
Pharmanv Euronext
,
Merck Keytruda
,
Franka Giordano
,
Guillaume Van Renterghem
,
Linkedin
,
American Society Of Clinical Oncology
,
Twitter
,
Department Of Radiation Oncology
,
Merck Sharp Dohme Corp
,
University Hospital Bonn
,
Euronext Growth Paris
,
Clinical Oncology
,
Annual Meeting
,
Radiation Oncology
,
Key Opinion Leader
,
Nline Results
,
First Line Glioblastoma Presented
,
Merck Sharp Dohme
,
Executive Officer
,
Media Relations
,
Noxxon
,
Dharma
,
Presents
,
Bull
,
Line
,
Results
,
Rom
,
Hase
,
Gloria
,
Trial
,
Glioblastoma
,
022
,
Disco
,
Nnual
,
Meeting
,
comparemela.com © 2020. All Rights Reserved.